The clinical trial sponsored by Shanghai BDgene Co., Ltd. aims to evaluate the safety and preliminary efficacy of BD113vLVP, a CRISPR/Cas9-based gene editing therapy, in patients with primary open-angle glaucoma (POAG) associated with MYOC gene mutations. The market for glaucoma treatments is significant, with a growing demand for innovative therapies that address the underlying genetic causes of the disease. If successful, BD113vLVP could position itself as a first-in-class therapy, potentially capturing a substantial share of the glaucoma treatment market, especially among patients with MYOC mutations. Competitive analysis indicates a limited number of gene-editing therapies targeting ocular conditions, suggesting a favorable landscape for BDgene's asset. However, the trial's outcomes will be critical for investor confidence and future funding opportunities.